drugset / Trial / NCT05251259

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

NCT05251259

Phase 2 Completed 670 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.

Timeline

Start
2022-01-27
Primary completion
2026-01-07
Completion
2026-01-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atuliflapon Small molecule Oral

Indications